Swiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron.
Independent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate this trend.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_online_thomas_schiessle.jpg1024768h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-07-15 16:03:002018-07-15 16:03:00Skilful asset swapping in the time of big data
Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.
https://european-biotechnology.com/wp-content/uploads/2024/04/20180712-genmab-immatics.jpg6751200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2018-07-12 08:29:002018-07-12 08:29:00Immunooncology: Genmab teams up with Immatics
Using only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk.
Norwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.
https://european-biotechnology.com/wp-content/uploads/2024/04/20180711-lifecare-going-public.jpg9001600Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2018-07-10 16:29:002018-07-10 16:29:00Lifecare floats on Oslo stock exchange
Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.
https://european-biotechnology.com/wp-content/uploads/2024/04/20180710-abingworth.jpg6751200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2018-07-10 08:29:002018-07-10 08:29:00Abingworth closes new biotech fund at €268m
After €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.
Two listed Scandinavian biotech companies are about to merge into one. Medical Prognosis Institute A/S (Nasdaq First North Stockholm) in Denmark and Oncology Venture Sweden AB (Aktie Torget) in Sweden aim to create what they call a one-stop-shop for personalised cancer treatments.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_07_09_OV.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-07-06 13:38:162024-04-02 16:21:18A match made in Scandinavia
Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.
https://european-biotechnology.com/wp-content/uploads/2024/04/20180706-gut.jpg12801920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2018-07-06 07:29:002018-07-06 07:29:00€7m for French microbiome start-up
The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_DDheadshot.jpg700700h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-07-05 16:41:292018-07-05 16:41:29Lundbeck names new president and CEO
Urovant launches US$150m IPO
Latest NewsSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron.
Skilful asset swapping in the time of big data
OpinionIndependent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate this trend.
Immunooncology: Genmab teams up with Immatics
Latest NewsDanish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.
Big Data: Tracking cancer risk genes
Latest NewsUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk.
Lifecare floats on Oslo stock exchange
Latest NewsNorwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.
Abingworth closes new biotech fund at €268m
Latest NewsBioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.
€47m for rare disease biotech
Latest NewsAfter €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.
A match made in Scandinavia
BackgroundTwo listed Scandinavian biotech companies are about to merge into one. Medical Prognosis Institute A/S (Nasdaq First North Stockholm) in Denmark and Oncology Venture Sweden AB (Aktie Torget) in Sweden aim to create what they call a one-stop-shop for personalised cancer treatments.
€7m for French microbiome start-up
Latest NewsMicrobiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.
Lundbeck names new president and CEO
AppointmentsThe Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.